To develop LXE408 as a potential new oral treatment for visceral leishmaniasis
current phase of drug development
updated 1 Jun 2021
DNDi and Novartis initiated a collaboration and licence agreement in early 2020 to jointly develop LXE408 – a first-in-class compound, discovered at Novartis with financial support from Wellcome – as a potential new oral treatment for visceral leishmaniasis.
News and publications
Get our latest news, personal stories, research articles, and job opportunities.